About Ymitter Therapeutics, Inc.

Ymitter therapeutics, is developing radioligand therapy to treat cancer with a peptide or small molecule as ligand to bind to a receptor protein on cancer cells. We compete in the rapidly growing radioligand therapy market, estimated at over $9.2 billion this year.